The broad range of key supports provided by the Clinical Translational Core ensures that its activities contribute to the productivity of virtually all investigators participating in Center activities. However, the degree of utilization of core resources varies considerably among projects and the following list includes only those that are relatively heavy users.
|
Principal |
Grant Number and Title |
Clinical Translational Core |
Genetics Core |
Translational Neuroscience Core |
Neuroimaging Core |
Behavior Science Core |
|
Comi |
Faneca 66 Foundation: Cannabidiol expanded access study in medically refractory Sturge-Weber syndrome |
X |
|
|
|
|
|
Comi |
Faneca 66 Foundation: Trial of sirolimus for cognitive impairments in Sturge-Weber syndrome |
X |
|
|
|
|
|
Everett |
R01 HD68446: GFAP Biomarker of Whole Body Cooling Outcome and Efficacy in the Neonate with HIE |
X |
|
|
X |
|
|
Ewen |
R21 NS091569: Direct Examination of Imitation Based Learning in ASD |
X |
|
|
X |
X |
|
Fatemi |
A Cure for Ellie Foundation: Characterization of the Natural History of Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation |
X |
|
|
|
|
|
Findling |
R01 MH073967: Longitudinal Assessment of Manic Symptoms |
X |
|
|
X |
|
|
Findling |
NCT02674633: Software Treatment for Actively Reducing Severity of ADHD (STARS-ADHD) |
X |
|
|
|
|
|
Findling |
Supernus Pharmaceuticals, SPN810P301: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment Objectives |
X |
|
|
|
X |
|
Findling |
Dasotraline Pediatric Extension Study |
X |
|
|
|
|
|
Findling |
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder |
X |
|
|
|
|
|
Harris |
Rubenstein Taybi Syndrome Foundation: Characterizing the Neurocognitive and Neurophysiologic Phenotype of Rubinstein-Taybi Syndrome |
X |
X |
|
|
X |
|
Johnston |
2K12 NS001696: Neurology Sciences Academic Development Award (NSADA) |
X |
X |
|
|
|
|
Johnston |
Kennedy Krieger Institute-Johns Hopkins Medicine Interdisciplinary Cerebral Palsy (CP) Center of Research Excellence (KKI-JHM CPCRE): Nanomedicine-Based Therapy for Perinatal White Matter Injury |
X |
|
X |
|
X |
|
Krinsky-McHale/Silverman |
P01 HD035897: Aging and Dementia in Adults with Down syndrome. Subproject 2: (8402) Validation of Criteria for Identifying “MCI” in Adults with Down syndrome. |
X |
|
|
|
X |
|
Lance |
1K23HL133455: Neuroimaging, Protein Biomarkers, and Neurodevelopment in Very Young Children with Sickle Cell Disease |
X |
|
|
X |
X |
|
Landa |
R01 MH059630: Autism social and communication predictors in siblings |
X |
|
|
|
|
|
Naidu |
R01 FD004247: PH2 Study of dextromethorpan in the treatment of Rett syndrome |
X |
X |
X |
|
X |
|
Sadowsky |
Ekso Bionics, 105333: Adherence to Home-Based Functional Electrical Stimulation (FES) Exercise in Patients with Spinal Cord Injury (SCI) |
X |
|
|
|
X |
|
Salpekar |
NCT03371836: Use of Clobazam in Treating Anxiety Comorbid with Pediatric Epilepsy |
X |
|
|
|
X |
|
Schupf/Lott/Silverman |
U01 AG051412: Biomarkers of Alzheimer’s disease in adults with Down syndrome |
X |
X |
|
X |
X |
|
Schupf/Silverman |
P01 HD035897: Aging and Dementia in Adults with Down syndrome. Subproject 4: (8404) Genetic Epidemiology of Alzheimer’s Disease in Down syndrome |
X |
|
|
|
|
|
Tycko/Silverman |
P01HD035897: Aging and dementia in adults with Down syndrome. Subproject 3: (8403) Epigenetic Modifiers in Down syndrome |
X |
|
|
|
|
|
Valle |
UM1 HG006542: Baylor-Johns Hopkins Center for Mendelian Genetics |
X |
X |
|
|
|
|
Wagner |
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy |
X |
|
|
|
|